{"id":319791,"date":"2024-10-07T12:52:32","date_gmt":"2024-10-07T17:52:32","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=319791"},"modified":"2025-06-19T23:57:41","modified_gmt":"2025-06-20T04:57:41","slug":"mifepristone-trial-blurring-line-abortion-contraception","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/mifepristone-trial-blurring-line-abortion-contraception\/","title":{"rendered":"New mifepristone clinical trial has goal of ‘blurring the line’ between abortion and contraception"},"content":{"rendered":"
<\/div>

Dutch abortionist Rebecca Gomperts, founder of the international abortion pill business Aid Access,\u00a0is testing<\/a> mifepristone (the active ingredient<\/a> in the first drug of the abortion pill regimen) for use as a contraceptive<\/em>. The 12-month clinical trial<\/a>, “Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive (WOMEN),” is sponsored by<\/a> Leiden University Medical Center. It expects to show that the “use of weekly mifepristone 50 mg as a contraceptive will be safe, effective, and acceptable.”<\/p>\n

Despite the dosage differences between the drugs, some speculate this will guarantee that mifepristone will remain accessible for abortions.<\/p>\n

Collaborators of the trial include Karolinska Institute in Sweden, the Children’s Investment Fund Foundation, and Women on Waves \u2014 another organization co-founded by Gomperts, who is acting as the principal investigator of the trial.<\/p>\n

The study will utilize “Mifepristone 50 mg” \u2014 a lower dosage than the mifepristone\/Mifeprex 200mg approved in the United States for use as the abortion pill. But could easy access to a 50mg pill allow it to be substituted for the 200mg dosage<\/a> approved in 2000<\/a> by the Food and Drug Administration (FDA) for the termination of pregnancy?<\/p>\n

\"Mifepristone

Mifepristone abortion pill as contraceptive Image from The Verge<\/p><\/div>\n

Children’s Investment Fund Foundation<\/strong><\/p>\n

On its website<\/a>, the Children’s Investment Fund Foundation (CIFF) claims to be “an independent philanthropic organisation, with offices in Addis Ababa, Beijing, London, Nairobi and New Delhi,” which “work[s] with a wide range of partners to transform the lives of children and adolescents.”<\/p>\n

CIFF was established<\/a> in 2002 by\u00a0Chris Hohn<\/a> and his then-wife<\/a> Jamie Cooper. The organization claims to have granted $416.6m to “Sexual and Reproductive Health Rights [SRHR]” \u2014 which always encompasses abortion<\/a>.<\/p>\n

In addition to taking part in the mifepristone 50mg contraceptive trial, CIFF is currently partnering<\/a> with the Bill and Melinda Gates Foundation, Pfizer,<\/a> and others on an injectable contraceptive. In addition, CIFF funds projects<\/a> with the eugenics-founded Population Council<\/a>, which brought the abortion pill (RU486) into the United States and set up its U.S. manufacturer, Danco Laboratories.<\/p>\n

According to Influence Watch<\/a> (emphasis added):<\/p>\n

After President Donald Trump reinstated the Mexico City Policy, a policy first outlined in the Reagan administration that requires foreign non-governmental organizations (NGOs) to assure they will not ‘perform or actively promote abortion as a method of family planning’ if they are to receive family planning aid from the United States, Hohn pledged $10 million towards the ‘She Decides’ movement, a pro-abortion-rights global fundraising initiative created by the Dutch Government.<\/strong><\/em><\/p>\n

Mifepristone contraceptive trial expands<\/strong><\/p>\n

“In May 2022, the Moldovan Department of Health gave approval for the clinical trial of mifepristone for contraception. More than 14 medical centers, including seven hospitals, have already committed to participate in the study. Researchers began enrolling patients in Moldova in August 2023 and hope to expand the study to the Netherlands soon, working with Leiden University Medical Centre. Researchers plan to include 949 women who will use mifepristone weekly for a year,” Ms. Magazine reported<\/a> in August. “Approval of mifepristone for contraception would also make it available as a\u00a0morning-after pill<\/a>, for use within 120 hours after unprotected intercourse, and to end an early pregnancy.”<\/p>\n

According to the clinical trial:<\/p>\n

Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. <\/em><\/p>\n

We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. <\/em><\/p>\n

We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. <\/em><\/p>\n

It is important to know how people experience that use of one tablet a week.<\/em><\/p>\n

\n
\n

"[Dr. Rebecca Gomperts] hopes this large clinical trial will confirm the safety and efficacy of using a low dose of mifepristone to prevent pregnancy," writes @CarrieNBaker<\/a> of @rebeccagomperts<\/a>' study of the medication as a #contraceptive<\/a>, taken once a weekhttps:\/\/t.co\/ecGqpiIKqC<\/a><\/p>\n

— CTI Exchange (@ctiexchange) February 9, 2024<\/a><\/p><\/blockquote>\n